Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes.

PURPOSE

We explored the use of intraventricular I-Omburtamab targeting B7-H3 in patients with ETMR.

METHODS

Patients were enrolled in an IRB approved, phase 1, 3 + 3 dose escalation trial. Patients with CNS disease expressing the antibody target antigen B7-H3 were eligible. We report on a cohort of three patients with ETMR who were enrolled on the study. Three symptomatic children (ages 14 months, 3 and 3.5 years) had large parietal masses confirmed to be B7-H3-reactive ETMR. Patients received 2 mCi I-Omburtamab as a tracer followed by one or two therapeutic I-Omburtamab injections. Dosimetry was based on serial CSF, blood samplings and region of interest (ROI) on nuclear scans. Brain and spine MRIs and CSF cytology were done at baseline, 5 weeks after I-Omburtamab, and approximately every 3 months thereafter. Acute toxicities and survival were noted.

RESULTS

Patients received surgery, focal radiation, and high dose chemotherapy. Patients 1 and 2 received I-Omburtamab (80 and 53 mCi, respectively). Patient 3 had a local recurrence prior to I-Omburtamab treated with surgery, external beam radiation, chemotherapy, then I-Omburtamab (36 mCi). I-Omburtamab was well-tolerated. Mean dose delivered by I-Omburtamab was 68.4 cGy/mCi to CSF and 1.95 cGy/mCi to blood. Mean ROI doses were 230.4 (ventricular) and 58.2 (spinal) cGy/mCi. Patients 1 and 2 remain in remission 6.8 years and 2.3 years after diagnosis, respectively; patient 3 died of progressive disease 7 months after therapy (2 years after diagnosis).

CONCLUSIONS

I-Omburtamab appears safe with favorable dosimetry therapeutic index. When used as consolidation following surgery and chemoradiation therapy, I-Omburtamab may have therapeutic benefit for patients with ETMR.